H2DCFDA-DCFH-DA-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEH2DCFDACat.No.:HY-D0940CASNo.:4091-99-0Synonyms:DCFH-DA;2',7'-Dichlorodihydrofluoresceindiacetate分?式:C??H??Cl?O?分?量:487.29作?靶點:ReactiveOxygenSpecies作?通路:Immunology/Inflammation;MetabolicEnzyme/Protease;NF-κB儲存?式:-20°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性數(shù)據(jù)體外實驗DMSO:125mg/mL(256.52mM;Needultrasonic)Ethanol:20mg/mL(41.04mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.0522mL10.2608mL20.5217mL5mM0.4104mL2.0522mL4.1043mL10mM0.2052mL1.0261mL2.0522mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C儲存時，請在6個?內使?，-20°C儲存時，請在1個?內使?。體內實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:2.08mg/mL(4.27mM);Suspendedsolution;Needultrasonic2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(4.27mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(4.27mM);ClearsolutionBIOLOGICALACTIVITY?物活性H2DCFDA(DCFH-DA)?種可滲透細胞的，?于檢測細胞內活性氧(ROS)的探針(Ex/Em=488/525nm)[1]。體外研究Guidelines(Followingisourrecommendedprotocol.Thisprotocolonlyprovidesaguideline,andshouldbemodifiedaccordingtoyourspecificneeds).1.H2DCFDAisdissolvedinDMSOtoobtaina10mMstocksolutionsandfurtherdilutedbeforeuse.2.Cellsareincubatedwith5μMH2DCFDAsolutioninPBSinthedarkfor30minat37°C,thenharvestedwith0.05%trypsin-EDTAsolution,suspendedinafreshmedium,andimmediatelyanalyzedwithflowcytometer.3.AlongwiththeH2DCFDAprobe,ifindicated,useROS-insensitivemodificationofthefluoresceindyeDCFDAasapositivecontrol.ThestainingprocedureisthesameasfortheH2DCFDA[1].PROTOCOLKinaseAssayROSMeasurements[1]ForthedetectionofintracellularROSlevel,ROS-sensitiveprobeH2DCFDAisused.Adherentcells(ESCs,difESCs,eMSCs,HeLa,U118)areincubatedwith5μMstainingsolutioninPBSinthedarkfor30minat37°C,thenharvestedwith0.05%trypsin-EDTAsolution,suspendedinafreshmedium,andimmediatelyanalyzedwithflowcytometer.Lymphocytes,bothcontrolandPHA-activated,areresuspendedinPBS,incubatedwith5μMofH2DCFDAinthedarkfor30minat37°C,andimmediatelyanalyzed.AlongwiththeH2DCFDAprobe,ifindicated,ROS-insensitivemodificationofthefluorescentdyeDCFDAisused.ThestainingprocedureisthesameasfortheH2DCFDA[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?Cell.2021Jun24;184(13):3528-3541.e12.?SignalTransductTargetTher.2022Aug15;7(1):288.?NanoEnergy.2022:108002.?ACSNano.2022Oct11.?ACSNano.2021Oct26;15(10):16286-16297.Seemorecustomervalidationsonwww.MedChemEREFERENCES2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[1].LyublinskayaOG,etal.Redoxenvironmentinstemanddifferentiatedcells:Aquantitativeapproach.RedoxBiol.2017Aug;12:758-769.McePdfHeightCaution:Producthasnotbeen